**Author details**

Abdelilah Arredouani1,2

1 Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar

2 College of Health and Life Sciences, Qatar Foundation, Hamad Bin Khalifa University, Doha, Qatar

\*Address all correspondence to: aarredouani@hbku.edu.qa

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment DOI: http://dx.doi.org/10.5772/intechopen.106445*

## **References**

[1] Kleiner DE, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clinics in Liver Disease. 2016;**20**(2):293-312

[2] Li B, Zhang C, Zhan YT. Nonalcoholic fatty liver disease cirrhosis: A review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Canadian Journal of Gastroenterology & Hepatology. 2018;**2018**:2784537

[3] Pinyopornpanish K et al. Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: A population-based study. BMC Gastroenterology. 2021;**21**(1):394

[4] Younossi ZM. Non-alcoholic fatty liver disease–a global public health perspective. Journal of Hepatology. 2019;**70**(3):531-544

[5] Younossi ZM et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;**64**(5):1577-1586

[6] Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Reports. 2020;**2**(6):100192

[7] Ota T. Molecular mechanisms of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). Advances in Experimental Medicine and Biology. 2021;**1261**:223-229

[8] Younossi ZM et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology. 2019;**71**(4):793-801

[9] Sung KC et al. Combined influence of insulin resistance, overweight/ obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;**35**(4):717-722

[10] DiStefano JK, Gerhard GS. NAFLD in normal weight individuals. Diabetology and Metabolic Syndrome. 2022;**14**(1):45

[11] Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Molecular Metabolism. 2021;**50**:101122

[12] Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism. 2016;**65**(8):1026-1037

[13] Carlsson B et al. Review article: The emerging role of genetics in precision medicine for patients with nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2020;**51**(12):1305-1320

[14] Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database of Systematic Reviews. 2011;**6**:Cd003619

[15] Dudekula A et al. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS One. 2014;**9**(11):e111808

[16] Chalasani N et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;**67**(1):328-357

[17] Parker HM et al. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology. 2012;**56**(4):944-951

[18] Lee CH et al. Effects of Omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: A systematic review and metaanalysis. Nutrients. 2020;**12**(9):2769

[19] Mäkelä TNK et al. Associations of serum n-3 and n-6 polyunsaturated fatty acids with prevalence and incidence of non-alcoholic fatty liver disease. The American Journal of Clinical Nutrition. June 1, 2022:1-12

[20] Dentin R et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. The Journal of Clinical Investigation. 2005;**115**(10):2843-2854

[21] Siriwardhana N, Kalupahana NS, Moustaid-Moussa N. Health benefits of n-3 polyunsaturated fatty acids: Eicosapentaenoic acid and docosahexaenoic acid. Advances in Food and Nutrition Research. 2012;**65**:211-222

[22] Li J et al. The role of vitamins in the pathogenesis of non-alcoholic fatty liver disease. Integrative Medicine Insights. 2016;**11**:19-25

[23] Raza S et al. Vitamins and non-alcoholic fatty liver disease: A molecular insight(⋆). Liver Research. 2021;**5**(2):62-71

[24] Abe RAM et al. The role of vitamins in non-alcoholic fatty liver disease: A systematic review. Cureus. 2021;**13**(8):e16855

[25] Miller ER 3rd et al. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine. 2005;**142**(1):37-46

[26] Burns J et al. Plant foods and herbal sources of resveratrol. Journal of Agricultural and Food Chemistry. 2002;**50**(11):3337-3340

[27] Elgebaly A et al. Resveratrol supplementation in patients with nonalcoholic fatty liver disease: Systematic review and meta-analysis. Journal of Gastrointestinal and Liver Diseases. 2017;**26**(1):59-67

[28] Andrade JM et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014;**30**(7-8):915-919

[29] Faghihzadeh F et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutrition Research. 2014;**34**(10):837-843

[30] Leoni S et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World Journal of Gastroenterology. 2018;**24**(30):3361-3373

[31] Anushiravani A et al. Treatment options for nonalcoholic fatty liver disease: A double-blinded randomized placebo-controlled trial. European Journal of Gastroenterology & Hepatology. 2019;**31**(5):613-617

[32] Feng W et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. Journal of Diabetes. 2017;**9**(8):800-809

[33] Feng WH et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver

*Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment DOI: http://dx.doi.org/10.5772/intechopen.106445*

disease: A randomized trial. Journal of Diabetes Investing. 2019;**10**(2):399-407

[34] Garinis GA et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: A randomized study. International Journal of Obesity. 2010;**34**(8):1255-1264

[35] Handzlik G et al. Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. Pharmacological Reports. 2019;**71**(2):183-188

[36] Haukeland JW et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scandinavian Journal of Gastroenterology. 2009;**44**(7):853-860

[37] Idilman R et al. Clinical trial: Insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2008;**28**(2):200-208

[38] Komorizono Y et al. Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study. Diabetes, Obesity & Metabolism. 2021;**23**(3):832-837

[39] Nadeau KJ et al. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatric Diabetes. 2009;**10**(1):5-13

[40] Bugianesi E et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. The American Journal of Gastroenterology. 2005;**100**(5):1082-1090

[41] Lavine JE et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA. 2011;**305**(16):1659-1668

[42] Gawrieh S et al. Relationship of enhanced liver fibrosis score with pediatric nonalcoholic fatty liver disease histology and response to vitamin E or metformin. The Journal of Pediatrics. 2021;**239**:161-167.e5

[43] Kinoshita T et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. Journal of Diabetes Investing. 2020;**11**(6):1612-1622

[44] Yan H et al. Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biology of Sex Differences. 2021;**12**(1):1

[45] Yoneda M et al. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): A randomized prospective open-label controlled trial. BMJ Open Diabetes Research & Care. 2021;**9**(1):e001990

[46] Della Pepa G et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: Clinical and pathophysiological insights from a subgroup of the TOSCA. IT randomised trial. Diabetes Research and Clinical Practice. 2021;**178**:108984

[47] Gastaldelli A et al. PPAR-γinduced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver International. 2021;**41**(11):2659-2670

[48] Syed-Abdul MM et al. Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities. Hepatology. 2020;**72**(1):103-118

[49] Ito D et al. Comparison of Ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, Active-Controlled Trial. Diabetes Care. 2017;**40**(10):1364-1372

[50] Portillo-Sanchez P et al. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. Journal of Diabetes. 2019;**11**(3):223-231

[51] Cusi K et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Annals of Internal Medicine. 2016;**165**(5):305-315

[52] Torres DM et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial. Hepatology. 2011;**54**(5):1631-1639

[53] Armstrong MJ et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of Hepatology. 2016;**64**(2):399-408

[54] Bouchi R et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: A randomized control trial. Endocrine Journal. 2017;**64**(3):269-281

[55] Fan H et al. Exenatide improves type 2 diabetes concomitant with

non-alcoholic fatty liver disease. Arquivos Brasileiros de Endocrinologia e Metabologia. 2013;**57**(9):702-708

[56] Guo W et al. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twentysix weeks: A randomized placebocontrolled trial. Diabetes Research and Clinical Practice. 2020;**170**:108487

[57] Hartman ML et al. Effects of novel dual GIP and GLP-1 receptor agonist Tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;**43**(6):1352-1355

[58] Khoo J et al. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. Diabetes, Obesity & Metabolism. 2017;**19**(12):1814-1817

[59] Khoo J et al. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver International. 2019;**39**(5):941-949

[60] Kuchay MS et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial). Diabetologia. 2020;**63**(11):2434-2445

[61] Smits MM et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: A randomised placebo-controlled trial. Diabetologia. 2016;**59**(12):2588-2593

[62] Yan J et al. Liraglutide, Sitagliptin, and insulin glargine added to metformin: The effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic

*Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment DOI: http://dx.doi.org/10.5772/intechopen.106445*

fatty liver disease. Hepatology. 2019;**69**(6):2414-2426

[63] Zhang LY et al. Effect of liraglutide therapy on serum fetuin a in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clinics and Research in Hepatology and Gastroenterology. 2020;**44**(5):674-680

[64] Eriksson JW et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study. Diabetologia. 2018;**61**(9):1923-1934

[65] Shibuya T et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes, Obesity & Metabolism. 2018;**20**(2):438-442

[66] Qiang S et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetology and Metabolic Syndrome. 2015;**7**:104

[67] Kuchay MS et al. Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;**41**(8):1801-1808

[68] Athyros VG et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;**71**:17-32

[69] Athyros VG et al. Statins: An underappreciated asset for the prevention

and the treatment of NAFLD or NASH and the related cardiovascular risk. Current Vascular Pharmacology. 2018;**16**(3):246-253

[70] Torres-Peña JD, Martín-Piedra L, Fuentes-Jiménez F. Statins in nonalcoholic steatohepatitis. Frontiers in Cardiovascular Medicine. 2021;**8**:777131

[71] Eslami L et al. Statins for nonalcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews. 2013;**12**:Cd008623

[72] Cho Y et al. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (ESSENTIAL study). BMC Medicine. 2022;**20**(1):93

[73] Loomba R et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;**61**(4):1239-1250

[74] Lucas C et al. A systematic review of the present and future of nonalcoholic fatty liver disease. Clinical and Experimental Hepatology. 2018;**4**(3):165-174

[75] Loomba R et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;**155**(5):1463-1473.e6

[76] Amin NB et al. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): Rationale and design of the phase II, dose-ranging, dose-finding,

randomised, placebo-controlled MIRNA (metabolic interventions to resolve NASH with fibrosis) study. BMJ Open. 2022;**12**(3):e056159

[77] Calle RA et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials. Nature Medicine. 2021;**27**(10):1836-1848

[78] Stiede K et al. Acetyl-coenzyme a carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study. Hepatology. 2017;**66**(2):324-334

[79] Matsumoto M et al. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis. PLoS One. 2020;**15**(1):e0228212

[80] Goedeke L et al. Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. Hepatology. 2018;**68**(6):2197-2211

[81] Tamura YO et al. Selective acetyl-CoA carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a preclinical nonalcoholic steatohepatitis model. The Journal of Pharmacology and Experimental Therapeutics. 2021;**379**(3):280-289

[82] Neokosmidis G, Cholongitas E, Tziomalos K. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit? World Journal of Gastroenterology. 2021;**27**(39):6522-6526

[83] Beysen C et al. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis

and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials. Diabetes, Obesity & Metabolism. 2021;**23**(3):700-710

[84] Loomba R et al. TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology. 2021;**161**(5):1475-1486

[85] Wiest R et al. Targeting the gut-liver axis in liver disease. Journal of Hepatology. 2017;**67**(5):1084-1103

[86] Okour M, Brigandi RA, Tenero D. A population analysis of the DGAT1 inhibitor GSK3008356 and its effect on endogenous and meal-induced triglyceride turnover in healthy subjects. Fundamental & Clinical Pharmacology. 2019;**33**(5):567-580

[87] Amin NB et al. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Science Translational Medicine. 2019;**11**(520):eaav9701

[88] Loomba R et al. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: A multicentre, double-blind, randomised, placebo-controlled phase 2 trial. The Lancet Gastroenterology & Hepatology. 2020;**5**(9):829-838

[89] Younossi ZM et al. Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis. Clinical Gastroenterology and Hepatology. Jul 15, 2021:S1542-3565

[90] Rinella ME et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from *Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment DOI: http://dx.doi.org/10.5772/intechopen.106445*

the REGENERATE study. Journal of Hepatology. 2022;**76**(3):536-548

[91] Hameed B et al. Clinical and metabolic effects associated with weight changes and obeticholic acid in nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2018;**47**(5):645-656

[92] Mudaliar S et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;**145**(3):574-82.e1

[93] Neuschwander-Tetri BA et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet. 2015;**385**(9972):956-965

[94] Pockros PJ et al. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver International. 2019;**39**(11):2082-2093

[95] Ratziu V et al. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemporary Clinical Trials. 2019;**84**:105803

[96] Siddiqui MS et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 2020;**72**(1):25-33

[97] Younossi ZM et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised,

placebo-controlled phase 3 trial. Lancet. 2019;**394**(10215):2184-2196

[98] Alam S et al. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Saudi Journal of Gastroenterology. 2016;**22**(1):69-76

[99] McPherson S et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS One. 2017;**12**(4):e0175717

[100] Wasta Esmail VA, Al-Nimer MSM, Mohammed MO. Effects of orlistat or Telmisartan on the serum free fatty acids in non-alcoholic fatty liver disease patients: An open-labeled randomized controlled study. The Turkish Journal of Gastroenterology. 2022;**33**(5):421-426

[101] Pydyn N et al. New therapeutic strategies in nonalcoholic fatty liver disease: A focus on promising drugs for nonalcoholic steatohepatitis. Pharmacological Reports. 2020;**72**(1):1-12

[102] Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews. Endocrinology. 2021;**17**(8):484-495

[103] Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Archives of Medical Research. 2021;**52**(1):25-37

[104] Fernández T et al. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and metaanalysis. PLoS One. 2022;**17**(2):e0263931

[105] Petersen KF et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia

by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;**54**(3):603-608

[106] Kleiner DE et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;**41**(6):1313-1321

[107] Katsagoni CN et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: A randomised controlled clinical trial. The British Journal of Nutrition. 2018;**120**(2):164-175

[108] Yaskolka Meir A et al. Effect of green-Mediterranean diet on intrahepatic fat: The DIRECT PLUS randomised controlled trial. Gut. 2021;**70**(11):2085-2095

[109] George ES et al. Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trial. Liver International. 2022;**42**(6):1308-1322

[110] Jimenez LS et al. Impact of weight regain on the evolution of non-alcoholic fatty liver disease after roux-en-Y gastric bypass: A 3-year follow-up. Obesity Surgery. 2018;**28**(10):3131-3135

[111] Marin-Alejandre BA et al. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver International. 2021;**41**(7):1532-1544

[112] Gjesing AP et al. Fasting and oral glucose-stimulated levels of glucosedependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits. Diabetologia. 2012;**55**(5):1338-1345

[113] Montemayor S et al. Effect of dietary and lifestyle interventions on the amelioration of NAFLD in patients with metabolic syndrome: The FLIPAN study. Nutrients. 2022;**14**(11):2223

[114] Noto D et al. Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A doubleblind randomised placebo-controlled trial. Nutrition, Metabolism, and Cardiovascular Diseases. 2022;**32**(5):1288-1291

[115] Mascaró CM et al. Effect of a six-month lifestyle intervention on the physical activity and fitness status of adults with NAFLD and metabolic syndrome. Nutrients. 2022;**14**(9):1813

[116] Kenđel Jovanović G et al. Metabolic and hepatic effects of energy-reduced anti-inflammatory diet in younger adults with obesity. Canadian Journal of Gastroenterology & Hepatology. 2021;**2021**:6649142

[117] Franco I et al. Physical activity and low glycemic index Mediterranean diet: Main and modification effects on NAFLD score. Results from a randomized clinical trial. Nutrients. 2020;**13**(1):66

[118] Ristic-Medic D et al. Calorierestricted Mediterranean and low-fat diets affect fatty acid status in individuals with nonalcoholic fatty liver disease. Nutrients. 2020;**13**(1):15

[119] Evert AB, Franz MJ. Why weight loss maintenance is difficult. Diabetes Spectrum: A Publication of the American Diabetes Association. 2017;**30**(3):153-156

[120] Lonardo A, Arab JP, Arrese M. Perspectives on precision medicine approaches to NAFLD diagnosis and management. Advances in Therapy. 2021;**38**(5):2130-2158

*Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment DOI: http://dx.doi.org/10.5772/intechopen.106445*

[121] Hallsworth K, Avery L, Trenell MI. Targeting lifestyle behavior change in adults with NAFLD during a 20-min consultation: Summary of the dietary and exercise literature. Current Gastroenterology Reports. 2016;**18**(3):11

[122] Borek AJ et al. Group-based diet and physical activity weight-loss interventions: A systematic review and meta-analysis of randomised controlled trials. Applied Psychology. Health and Well-Being. 2018;**10**(1):62-86

[123] Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Current Diabetes Reports. 2021;**21**(5):15
